Browse the evidence

Digital behavioral interventions are as effective as nondigital behavioral interventions for reducing overall cardiovascular risk factors, with no significant difference found across 11 key metrics.

You can use digital tools (apps, wearables, web platforms) to manage heart health risks just as effectively as traditional face-to-face programs or printed materials. The key is consistency and using evidence-based behavioral strategies, regardless of the delivery method.

Higher intake of red or processed meat is associated with increased all-cause, cardiovascular, and cancer-related mortality, but this association is largely explained by confounding factors such as smoking, obesity, and alcohol consumption rather than the protein itself.

While high intake of red and processed meats is linked to higher mortality, this risk appears to be driven largely by associated lifestyle factors like smoking, obesity, and alcohol use rather than the protein itself. Focus on maintaining a healthy weight, avoiding smoking, and limiting alcohol, as these factors likely explain the observed risks more than the meat consumption alone.

Higher intake of poultry, milk, and cheese is associated with reduced mortality risk in unadjusted models, but this protective effect is also substantially attenuated after adjusting for lifestyle confounders.

While high intake of poultry, milk, and cheese is linked to lower mortality in initial analyses, this benefit appears to be driven largely by associated lifestyle factors like not smoking, healthy weight, and moderate alcohol use rather than the food itself. Focus on maintaining a healthy lifestyle, as these factors likely explain the observed benefits more than the specific foods alone.

A longitudinal dietary pattern characterized by decreasing low-carbohydrate intake and increasing high-fat intake is associated with a lower risk of all-cause mortality in males, despite being associated with a higher risk of obesity.

For men in this demographic, shifting dietary habits to reduce carbohydrate intake (specifically from a low baseline) while allowing fat intake to increase over time is associated with a lower risk of death, though it comes with a higher risk of obesity. This suggests that for long-term survival, macronutrient quality and trajectory may matter more than total fat avoidance, but weight management remains a challenge.

A longitudinal dietary pattern characterized by decreasing very high-carbohydrate intake and a U-shape protein trajectory is associated with a significantly higher risk of diabetes in males.

For men, starting with a very high carbohydrate diet, even if you reduce it over time, may increase your risk of developing diabetes, especially if your protein intake follows a U-shaped pattern (high, then lower, then higher). This suggests that managing initial carbohydrate load and protein quality/timing is crucial for diabetes prevention.

A longitudinal dietary pattern characterized by decreasing very high-carbohydrate intake and moderate protein intake is associated with a higher risk of diabetes in females.

For women, starting with a very high carbohydrate diet, even if you reduce it over time, may increase your risk of developing diabetes, even if your protein intake remains moderate. This suggests that managing initial carbohydrate load is crucial for diabetes prevention in women.

High-bar and low-bar back squats produce equivalent muscle activation (EMG) during 6-RM sets, making both valid for muscular development despite kinematic differences.

If your goal is building muscle, you can use either high-bar or low-bar squats. They activate the same muscles when you lift to failure (6 reps). Choose the style that feels better for your joints or allows you to lift more weight for your strength goals.

Fatigue manifests earlier in high-bar squats during 6-RM sets, causing kinematic breakdown (slower velocity, altered joint angles) in the final repetitions, whereas low-bar squats maintain kinematics better under fatigue.

If you are doing high-rep sets (like 6 reps) and notice your form breaking down or speed dropping significantly on high-bar squats, consider switching to low-bar. Low-bar squats tend to maintain better mechanical stability as you get tired.

GLP-1 receptor agonists (semaglutide, tirzepatide, retatrutide) cause significant loss of lean muscle mass (up to 40% of total weight loss), which contributes to reduced resting energy expenditure and increased risk of sarcopenia and weight regain.

If you are taking GLP-1 drugs, expect to lose some muscle along with fat. To protect your metabolism and strength, you must prioritize resistance training and adequate protein intake during your weight loss journey.

Skeletal muscle loss during pharmacologically induced weight loss is clinically significant because excessive SMM loss reduces resting energy expenditure (REE), making weight maintenance more difficult.

To maintain weight loss, preserving muscle is critical because muscle burns calories at rest. If you lose too much muscle, your metabolism slows down, making it harder to stay lean. Ensure your weight loss plan includes adequate protein and resistance training to protect muscle mass.

Dietary protein intake and resistance exercise can attenuate fat-free mass and skeletal muscle loss during caloric restriction, but may not completely abrogate it.

To minimize muscle loss while dieting, aim for higher protein intake (potentially 2-3x the standard recommendation) and incorporate resistance training. Note that even with these efforts, some muscle loss is likely unavoidable during significant weight reduction.

Semaglutide induces body weight loss and metabolic remodeling beyond caloric restriction alone, driven by intake-independent mechanisms including adipose tissue browning, increased sympathetic innervation, and sustained locomotor activity.

Semaglutide provides metabolic benefits that go beyond simply eating less. It promotes fat loss through biological changes like increasing brown fat activity and reducing fat cell size, independent of how much you eat. This suggests that patients may achieve better results with semaglutide than with dieting alone, even if their food intake is similar.

The 'borderline stage' of obesity (BMI 28-31.9 kg/m²) is a critical transitional phase characterized by elevated triglycerides, insulin resistance, and low-grade chronic inflammation, representing a vital window for early intervention to prevent clinical obesity.

If your BMI is between 28 and 31.9, do not assume you are safe. Look for metabolic red flags: high triglycerides, insulin resistance, or low-grade inflammation. This is your window to intervene with lifestyle changes (diet, activity) before clinical obesity and its complications set in.

Discontinuation of semaglutide or tirzepatide after 3-12 months of treatment results in negligible average weight change (mean +0.5% for obesity indication, -1.3% for T2D) over the subsequent year, driven by high rates of medication reinitiation (19.6%) or switching to alternative treatments (35.2%).

If you stop semaglutide or tirzepatide, do not assume you will regain all your weight. In clinical practice, most patients either restart the medication or switch to another treatment, which keeps average weight change very small (near zero) over the next year. However, individual results vary widely, so you must actively engage with your healthcare provider to select a replacement strategy (medication or lifestyle) immediately upon discontinuation to avoid regain.

Tirzepatide (a dual GIP/GLP-1 agonist) is better tolerated regarding GI side effects compared to semaglutide (a GLP-1 agonist), likely due to GIP receptor activation having anti-emetic properties.

If you struggle with stomach issues on Semaglutide (Ozempic/Wegovy), ask your doctor about Tirzepatide (Mounjaro/Zepbound). Clinical trials show it causes fewer GI side effects and fewer people stop taking it, possibly because of how it interacts with GIP receptors in the gut.

Shifting the Australian population's BMI to an optimal level of ≤25 kg/m² yields substantial health gains, specifically 2.00 million undiscounted Health Adjusted Life Years (HALYs) over 20 years and 20.4 million over the remaining lifetime.

For public health policy, this simulation confirms that population-wide strategies to maintain a BMI under 25 kg/m² are among the most effective interventions for extending healthy life. The benefits are not just individual but systemic, significantly reducing the burden of chronic diseases like heart disease, diabetes, and osteoarthritis, with the greatest relative health improvements occurring in socioeconomically disadvantaged communities.

GLP-1 receptor agonists (GLP-1RAs) significantly reduce body weight, BMI, and waist circumference in patients with psychiatric disorders and obesity, with efficacy comparable to or slightly lower than that observed in non-psychiatric populations.

If you have a psychiatric condition and are overweight, GLP-1 medications (like semaglutide or liraglutide) are a proven, effective option for losing weight, even if you take other psychiatric meds. You will likely lose about 5 kg (11 lbs) on average, which is less than in people without mental health conditions, but still significant. Side effects like nausea are common but usually mild and don't cause most people to stop treatment. Discuss this with your doctor as a priority for metabolic health.

A clinical risk model predicting new-onset diabetes (using HbA1c, fasting glucose, age, BMI, and TG/HDL ratio) identifies patients who derive significantly greater absolute risk reduction from pharmacological weight loss therapy (lorcaserin) compared to low-risk patients, despite similar hazard ratios.

If you have cardiovascular risk factors and are considering weight loss medication, ask your doctor about your specific risk of developing diabetes. A simple calculation using your age, BMI, and blood markers can show if you are likely to get significant absolute protection from diabetes by using weight-loss drugs. High-risk patients gain much more absolute benefit than low-risk patients, even if the relative effectiveness looks similar.

High-risk patients on blood pressure, lipid, or glucose-lowering medications in primary care settings frequently fail to achieve guideline-recommended lifestyle and medical risk factor targets, indicating a significant gap between evidence-based guidelines and clinical practice.

If you are at high risk for heart disease, taking medication is not enough. You must also address lifestyle factors like smoking, weight, and physical activity. The study shows that most people on medication still fail to reach health targets. Focus on quitting smoking, maintaining a healthy weight, and staying active alongside your medical treatment.

Large-scale lifestyle interventions (diet and exercise) significantly reduce the risk of disease progression and microvascular complications in high-risk populations, but fail to significantly reduce macrovascular complications or mortality compared to usual care, primarily due to low adherence.

Lifestyle changes (diet and exercise) are highly effective at preventing diabetes progression and improving heart failure outcomes, but they often fail to extend life or prevent heart attacks in large groups because people struggle to stick with them long-term. To succeed, prioritize consistency and adherence over intensity, as the benefits are 'overwhelming' when you actually follow the plan.

Pharmacotherapy for obesity is indicated for patients with BMI >= 30 kg/m2 or >= 27 kg/m2 with comorbidities, and efficacy is defined as >= 5% weight loss after 3 months.

If your BMI is 30+ (or 27+ with health issues), ask about medication. It's not a failure; it's a tool. If you don't lose at least 5% in 3 months, the drug isn't working for you.

Bariatric surgery is indicated for patients with BMI >= 40 kg/m2 or >= 35 kg/m2 with comorbidities, and offers benefits beyond weight loss including glycemic control and improved life expectancy.

If your BMI is 40+ (or 35+ with health issues), surgery is a valid option. It's not just weight loss; it can fix diabetes and other issues. Choose an experienced surgeon and commit to long-term follow-up.

Most plant-based meat analogues on the market have insufficient protein quality or quantity compared to animal meat, and very few are fortified with essential micronutrients like Vitamin B12 or Iron.

Do not assume plant-based meats are nutritionally complete. Check labels for Vitamin B12 and Iron fortification, as only 12% of products include them. Also, verify protein quality; many analogues have lower digestible indispensable amino acid scores (DIAAS) than meat. If you eat these frequently, consider a B12 supplement and ensure you are getting enough total protein.

Effective obesity prevention and treatment programs are more effective in children than in adults.

If you are trying to manage weight, know that interventions tend to work better for children. For adults, more complex or sustained strategies may be needed.